Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,928 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL. Swanson CJ, et al. Among authors: lai ryk. Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8. Alzheimers Res Ther. 2021. PMID: 33865446 Free PMC article. Clinical Trial.
Correction to: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL. Swanson CJ, et al. Among authors: lai ryk. Alzheimers Res Ther. 2022 May 21;14(1):70. doi: 10.1186/s13195-022-00995-9. Alzheimers Res Ther. 2022. PMID: 35598024 Free PMC article. No abstract available.
The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation.
Nathan PJ, Boardley R, Scott N, Berges A, Maruff P, Sivananthan T, Upton N, Lowy MT, Nestor PJ, Lai R. Nathan PJ, et al. Among authors: lai r. Curr Alzheimer Res. 2013 Mar;10(3):240-51. doi: 10.2174/1567205011310030003. Curr Alzheimer Res. 2013. PMID: 23521503 Clinical Trial.
Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027: Confirmation of Target Engagement and Selection of Phase 2 Dose in Dementia With Lewy Bodies Trial.
Landry IS, Aluri J, Schuck E, Ino M, Horie K, Boyd P, Reyderman L, Lai R. Landry IS, et al. Among authors: lai r. Alzheimer Dis Assoc Disord. 2022 Jul-Sep 01;36(3):200-207. doi: 10.1097/WAD.0000000000000515. Epub 2022 Jun 9. Alzheimer Dis Assoc Disord. 2022. PMID: 35700341 Clinical Trial.
Lewy Body Dementia Association's Industry Advisory Council: proceedings of the second annual meeting.
Goldman JG, Boeve BF, Armstrong MJ, Galasko DR, Galvin JE, Irwin DJ, Leverenz JB, Marder K, Abler V, Biglan K, Irizarry MC, Keller B, Lai R, Munsie L, Belleville M, Chaney O, Richard I, Taylor A, Graham T. Goldman JG, et al. Among authors: lai r. Alzheimers Res Ther. 2021 Jul 8;13(1):124. doi: 10.1186/s13195-021-00868-7. Alzheimers Res Ther. 2021. PMID: 34238345 Free PMC article.
1,928 results